A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Somatrogon (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors OPKO Health
Most Recent Events
- 24 Jul 2024 Status changed from active, no longer recruiting to completed.
- 06 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 14 Sep 2023 This trial has been completed in Bulgaria, according to European Clinical Trials Database record